You are here: Home: LCU 2 | 2006 : Case 4: Select publications

SELECT PUBLICATIONS

Dornbusch D et al. How do U.S. medical oncologists learn and apply new clinical trials information from press releases in nonmedical media? A case study based on ECOG 4599. Oncologist 2006;11(1):31-8. Abstract

Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent nonsmall- cell lung cancer. J Clin Oncol 2005;23(11):2544-55. Abstract

Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab? Oncologist 2004;9(Suppl 1):19-26. Abstract

Johnson DH et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91. Abstract

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599. Presentation. ASCO 2005;Abstract 4.

Table of Contents

Top of Page